COMP <GO>
GILD vs MRNA // DIVIDEND YIELD & FCF PAYOUT SAFETY
Gilead Sciences Inc. (NASDAQ) VS. Moderna Inc. (NASDAQ) • 15-METRIC TALLY: GILD 11
— MRNA 2
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: GILD
LAST: $170.68 (+3.06%) • MKT CAP: $205.35B
dividend-safety
1.95%
LAST: $221.72 (-0.47%) • MKT CAP: $88.93B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GILD VS. MRNA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GILD | MRNA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.80% | 55.30% | +23.50 | GILD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.00% | -34.10% | +55.10 | GILD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 4.60% | -2.32% | +6.92 | GILD | /fcf-yield <GO> |
| Operating Margin | 34.00% | -60.00% | +94.00 | GILD | /operating-margins <GO> |
| Net Profit Margin | 28.90% | -60.00% | +88.90 | GILD | /net-margins <GO> |
| Revenue Growth (YoY) | 2.40% | -39.90% | +42.30 | GILD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 1.95% | 0.00% | +1.95 | GILD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.87 | 15.07 | -9.20 | MRNA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | GILD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.3 | 57.7 | +6.60 | GILD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 1.10 | -0.22 | MRNA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.4x | 32.0x | -9.60 | GILD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $205.35B | $88.93B | $116.42B | GILD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GILD REV | MRNA REV | GILD GROSS % | MRNA GROSS % | GILD FCF | MRNA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $29.44B | $1.94B | 78.8% | 55.3% | $9.46B | -$2.06B |
| FY 2024 | $28.75B | $3.24B | 78.3% | 54.8% | $10.30B | -$4.05B |
| FY 2023 | $27.12B | $6.85B | — | — | $6.79B | -$3.43B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GILD // BETA 0.88
MRNA // BETA 1.10